Hyderabad: India’s second-largest drugmaker Dr Reddy’s Laboratories Ltd on Friday said its cardiovascular treatment DRL-17822 has entered the second stage of clinical trials.
DRL-17822 belongs to a class of drugs called cholesteryl ester transfer protein (CETP) inhibitors, used to help reduce bad cholesterol and increase good cholesterol, thereby reducing the risk of heart attacks in patients suffering from type-II dyslipidemia. Patients with this disorder have high blood cholesterol and triglyceride levels.
The phase-II study to evaluate the efficacy and safety of DRL-17822 will be carried out on 160 patients in Europe with type-II dyslipidemia, the Hyderabad-based company said in a statement.
“This class of therapy could transform the treatment of CHD (coronary heart disease) and DRL-17822 is in a position to be one of the front-running products in the class,” K. Anji Reddy, founder-chairman of Dr. Reddy’s Laboratories, said in the statement.